Homologous recombination repair gene alterations in prostate cancer: expert recommendations for genetic and biomarker testing

PURPOSE OF REVIEW: Homologous recombination repair (HRR) gene alterations are associated with genomic instability and more aggressive prostate cancer (PCa) leading to worse clinical outcomes. poly(ADP-ribose) polymerase inhibitors have demonstrated significant clinical benefit in patients with HRR-altered tumors, and international guidelines now recommend HRR testing. Nevertheless, real-world adoption of this testing remains inconsistent across healthcare systems. To address this gap, we developed expert-driven, practical recommendations for integrating HRR testing into clinical practice for patients with PCa. RECENT FINDINGS: The panel developed consensus recommendations addressing the optimal timing of HRR testing, patient selection criteria, appropriate use of genetic and biomarker testing platforms, and interpretation of test results. Hypothetical case studies illustrated application in clinical settings. These recommendations are evidence-based but reflect expert opinion and should be tailored to local circumstances. No statistical analyses were performed; generalizability may be influenced by differences between healthcare systems. SUMMARY: These expert consensus recommendations provide practical guidance on facilitating the broader and more consistent implementation of HRR testing in men with PCa. Wider adoption of such testing may enable more personalized treatment approaches and lead to improved patient outcomes.

Authors

Institutions

Publication Details

Journal
Current Opinion in Urology
Published
2026-11-19
DOI
https://doi.org/10.1097/mou.0000000000001465
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Homologous recombination repair gene alterations in prostate cancer: expert recommendations for genetic and biomarker testing

Marc‐Oliver Grimm, Joshua Michael Lang, Erik Briers, Todd Matthew Morgan et al.
5 links
Current Opinion in Urology
PARP inhibition in cancer therapy
article

Homologous recombination repair gene alterations in prostate cancer: expert recommendations for genetic and biomarker testing

Marc‐Oliver Grimm, Joshua Michael Lang, Erik Briers, Todd Matthew Morgan, Niven Mehra, Shahrokh F. Shariat, Shel Liang, Alexander W. Wyatt
article en

Abstract

PURPOSE OF REVIEW: Homologous recombination repair (HRR) gene alterations are associated with genomic instability and more aggressive prostate cancer (PCa) leading to worse clinical outcomes. poly(ADP-ribose) polymerase inhibitors have demonstrated significant clinical benefit in patients with HRR-altered tumors, and international guidelines now recommend HRR testing. Nevertheless, real-world adoption of this testing remains inconsistent across healthcare systems. To address this gap, we developed expert-driven, practical recommendations for integrating HRR testing into clinical practice for patients with PCa. RECENT FINDINGS: The panel developed consensus recommendations addressing the optimal timing of HRR testing, patient selection criteria, appropriate use of genetic and biomarker testing platforms, and interpretation of test results. Hypothetical case studies illustrated application in clinical settings. These recommendations are evidence-based but reflect expert opinion and should be tailored to local circumstances. No statistical analyses were performed; generalizability may be influenced by differences between healthcare systems. SUMMARY: These expert consensus recommendations provide practical guidance on facilitating the broader and more consistent implementation of HRR testing in men with PCa. Wider adoption of such testing may enable more personalized treatment approaches and lead to improved patient outcomes.

Current Opinion in Urology
Al-Ahliyya Amman University (JO), University of Wisconsin–Madison (US), University of British Columbia (CA), Pfizer (United States) (US), Charles University (CZ), University of Michigan (US), Radboud University Medical Center (NL), University of Wisconsin Carbone Cancer Center (US), Jena University Hospital (DE), Weill Cornell Medicine (US), Vancouver Prostate Centre (CA), Medical University of Vienna (AT), The University of Texas Southwestern Medical Center (US)
Good health and well-being
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon